Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC pediculicides

This article was originally published in The Tan Sheet

Executive Summary

NDMA submits citizen's petition to FDA and EPA on April 22, urging the agencies to "develop and implement a specific set of coordinating steps for the administrative transfer" of regulatory authority for pediculicides from EPA to FDA when the final OTC monograph on pediculicides becomes effective on Dec. 14. Actions requested in the petition echo those discussed at an April 14 "OTC feedback" meeting: an EPA stay of enforcement on FDA-labeled products prior to the effective date and a one-year grace period from FDA for EPA-labeled products in interstate commerce ("The Tan Sheet" April 18, p. 15). NDMA requested "expedited review" of the petition based on public health concerns and the "unique character of OTC pediculicide production and marketing"

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel